companydata.dkcompanydata.dk

ICEPHARMA A/S: Financial statements 2024

CVR: 36393459

Source: annual report 2024, Danish Business Authority

01/01/2024 – 31/12/2024

ICEPHARMA A/S (CVR 36393459) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -409,891 and a net result of DKK -3,562,543 compared with DKK -5,428,101 the year before. Equity in the 2024 report amounted to DKK 3,744,808. The solvency ratio was 73.8%. The company had 5 employees in the financial year.

Gross Profit
DKK -409,891
Profit/Loss
DKK -3,562,543
Equity
DKK 3,744,808
Total Assets
DKK 5,077,297
Employees
5

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2024--410 t.-3.6 mio.3.7 mio.5
2023--2.2 mio.-5.4 mio.2.2 mio.5
2022--1 mio.-4.7 mio.1.6 mio.5
2021--2.4 mio.-5.4 mio.690 t.5
2020--2.2 mio.-5.7 mio.7 t.5

Official annual report

View the official annual report directly on the page with a Pro subscription.

Screen every Danish company

Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.

Try company screening

Events in 2024

ICEPHARMA A/S: The 2023 annual report is outJul 25, 2024

ICEPHARMA A/S has published its annual report for 2023. Gross profit came to DKK -2,175,526, and the net result was DKK -5,428,101.

About ICEPHARMA A/S

ICEPHARMA A/S is a Danish company of the type Aktieselskab based in Taastrup, founded in 2014. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Hörður Þórhallsson. The board consists of Kristján Johannsson (chair), Jóhann Ingi Kristjánsson and Petrea Ingileif Gudmundsdottir. The company is owned by Eignarhaldsfélagið Lyng ehf. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK 1,000,033 and a net result of DKK 1,883,876 compared with DKK -3,562,543 the year before. Equity in the 2025 report amounted to DKK 10,304,500.

Source: annual report 2025, Danish Business Authority